Therapeutic development of adrenomedullin for moderate pneumonia caused by COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19
- Registration Number
- JPRN-jRCT2071210038
- Lead Sponsor
- Kita Toshihiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Hospitalized patients with moderate COVID-19 pneumonia and within 10 days after onset
Exclusion Criteria
patients with severe COVID-19 pneumonia
patients with liver dysfunction (AST and/or ALT > 5 times of reference values)
patients with renal dysfunction (serum creatinine > 2.0 mg/dl)
patients with severe ECG abnormalities and/or cardiac diseases
patients with malignancy or history of malignancy
patients who are expected to transfer to other hospital within 72 hours
pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Period of oxygen administration (days)
- Secondary Outcome Measures
Name Time Method the distribution of clinical status assessed on the 6-point ordinal scale on study day 10, 20 and 30<br>The changes of cytokines<br>Adverse events